Investor Demands Governance Changes at Pacira BioSciences Amid Disappointing Performance

Investor Push for Governance Overhaul at Pacira BioSciences Amid Performance Woes

DOMA Perpetual Capital Management LLC raises significant alarms regarding the operational and governance status of Pacira BioSciences, a biopharmaceutical company specializing in non-opioid pain management solutions. Holding approximately 7.1% of Pacira's outstanding common shares, DOMA has expressed discontent with the company’s performance, which has seen a staggering decline of 56% over the past decade and a 68% drop in the last five years. Under the leadership of CEO Frank Lee, the stock falls further, with a reported 30% decrease during his tenure. DOMA attributes these troubling figures to consistently missed earnings forecasts, downgrades in financial guidance, and a lack of profitability that has persisted for two years.

The investor group argues that these financial challenges signal a deeper issue regarding governance and oversight within Pacira’s board. They assert that the board has failed to provide adequate oversight and responsiveness to shifting market conditions, which has exacerbated shareholders' concerns. DOMA criticizes the board for neglecting its fiduciary duties and allows excessive executive compensation to continue amidst financial struggles, further alienating investor trust. As a remedy, DOMA emphasizes the urgent need for accountability and governance reforms, advocating for a reevaluation of Pacira's current strategies to adequately address profitability and restore investor confidence.

In a decisive move, DOMA nominates three candidates for Pacira's board: Christopher Dennis, Oliver Benton Curtis, and Eric de Armas. These nominees are chosen for their expertise in capital allocation, risk management, and legal affairs, which DOMA believes are crucial for enacting the necessary changes. The activist investor calls for immediate leadership changes, suggesting that Frank Lee should be replaced and a formal sale process for the company should be initiated alongside appointing an interim CEO. This approach, according to DOMA, is vital to protect shareholders’ interests and ensure that Pacira BioSciences can meet critical financial and operational benchmarks moving forward.

As the situation unfolds, Pacira BioSciences faces mounting pressure to address governance weaknesses while also recalibrating its operational strategies. Stakeholders maintain keen scrutiny of the company's response, as the implications of these proposed changes could potentially reshape the company's trajectory amid an increasingly competitive market. In light of these developments, shareholders are urged to remain vigilant as the board navigates a path toward rectifying long-standing concerns about its governance and operational efficacy.